ArticleJournal of thoracic disease2010
Current status of immunotherapy for the treatment of lung cancer.
Article in Journal of thoracic disease, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 28 citations in OpenAlex.
- New Development of Biomarkers for Gastrointestinal Cancers: From Neoplastic Cells to Tumor Microenvironment.Biomedicines · 2018Review
- Predictive factors of activity of anti-programmed death-1/programmed death ligand-1 drugs: immunohistochemistry analysis.Translational lung cancer research · 2015Review
- Mycobacterium bovis BCG promotes tumor cell survival from tumor necrosis factor-α-induced apoptosis.Molecular cancer · 2014Article
- The translation elongation factor eEF2 is a novel tumor‑associated antigen overexpressed in various types of cancers.International journal of oncology · 2014Article
- Actual status of therapeutic vaccination in non-small cell lung cancer.Contemporary oncology (Poznan, Poland) · 2014Review
- Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma.Annals of the New York Academy of Sciences · 2013Review
- [Lung cancer. Molecular pathology and personalized therapy].Der Internist · 2013Article
- The role of natural killer cells in pulmonary immunosurveillance.Frontiers in bioscience (Scholar edition) · 2013Review
- The efficacy of the inhalation of an aerosolized Group A streptococcal preparation in the treatment of lung cancer.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2012Article
- The therapeutic function of the chemokine RANTES on the H22 hepatoma ascites model.Molecular and cellular biochemistry · 2012Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunotherapy is a novel approach for the treatment of systemic malignancies. Passive and adaptive immunotherapy have been applied to the treatment of a wide variety of solid tumors such as malignant melanoma (1), renal cell carcinoma (2) and ovarian cancer (3). Several early clinical trials of immune based therapy for both non-small (NSCLC) and small cell lung cancer (SCLC) have demonstrated limited or no success (3),(4) but recent trials of antigen-specific cancer immunotherapy have shown early therapeutic potential and are now being rigorously evaluated on a larger scale (5). In this communication we briefly review the historic aspects of immune based therapy for solid cancer, describe therapeutic strategies aimed at targeting lung cancer, and discuss limitations of current therapy and future directions of this field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.